论文部分内容阅读
With multiple companies developing similar therapeutics to the same target and patent ticking toward expiration, speed is critical for therapeutic development.A well-positioned program needs to secure timely and high-quality support to assure fast pace development.We have developed a comprehensive toolkit from full-length protein immunogen production to preclinical antibody production, from high affinity rabbit mAbs to fully human mAbs derived from single B-cell cloning, and from antibody characterization to cell based assay.We have also developed one of the biggest protein and antibody banks with over 1500 proteins and over 1000 antibodies.This bank serves both as therapeutic targets for mAb development and as research reagents.In the past three years, we have contract manufactured over 800 preclinical mAbs for clients including 7 of global top 10 pharmas.In this talk, development strategies for different technologies and their integration would be discussed.